Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Rutaevin
Cat. No.:
0225LY-1157
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Rutaevin exhibits significant inhibitory activity against nitric oxide production in activated macrophages, highlighting its potential value as a therapeutic anti-inflammatory agent.
Synonym:
33237-37-5; (1R,2R,7S,10R,12R,13S,14R,16S,19S,20S)-19-(furan-3-yl)-12-hydroxy-9,9,13,20-tetramethyl-4,8,15,18-tetraoxahexacyclo[11.9.0.02,7.02,10.014,16.014,20]docosane-5,11,17-trione; 12-(Furan-3-yl)-8-hydroxy-6,6,8a,12a-tetramethyldecahydro-1H,3H-oxireno[c]pyrano[4'',3'':2',3']furo[3',4':5,6]naphtho[1,2-d]pyran-3,7,10(8H,9aH)-trionato
CAS No.:
33237-37-5
Compound CID:
441805
Formula:
C26H30O9
Formula Weight:
486.51
Specification
Relative Density:
1.44 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Rutaevin can be used in natural product research to explore its bioactivity in managing metabolic and inflammatory disorders.
Library Information
Target:
NO synthase; Oxidative stress
Receptor:
NOS family
Pathways:
Immunology/Inflammation; NF-κB signaling; Metabolism
Plate Number:
AOCL-15
Plate Location:
h4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 123.33 mM
